DOCSLIB.ORG

Roseman-University-2019-Abstract

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Roseman-University-2019-Abstract Wednesday, March 6, 2019 Table of Contents Welcome from President Renee Coffman…………………………………………….3 Welcome from the Research Symposium Chairs..………………………………..4 Keynote Speakers…………………………………………………………………………………5 Utah Abstracts…………………………..………………..……….………………………….....7 Nevada Abstracts………………………………………………………………………..……..86 Roseman University Research Symposium 2019 Program 2 Friends and Colleagues, Welcome to the Fifth Annual Roseman University of Health Sciences Research Symposium. We are pleased and grateful to continue the momentum that has been building since our first Symposium five years ago. This year, we received 136 abstracts to date across our three campuses in South Jordan, UT and Henderson & Summerlin, NV as well as from a growing contingent from our colleagues outside of Roseman. We look forward to featuring the discoveries and scholarly work of our faculty members, staff, post-doctoral researchers, residents, and students from all of Roseman’s health disciplines. Many of the presenting authors both inside and outside of Roseman carry affiliations with other great universities and entities worldwide. Our presenters are immensely talented and in demand, working across borders to create solutions, collaborating with other great minds, and bridging our communities. This year’s abstracts cover a wide range of topics in various areas including bench-top science, clinical research, and educational research. These works independently and collectively represent prodigious planning, methodical execution, and deeply insightful findings. With a wide breadth and depth of scientific subject matter, they are steps towards solutions, solutions that advance not only our work and our national and international reputation, but advance the human race. Some of these presentations address a number of diseases including PTSD, HIV/AIDS, diabetes, cancer, depression and fatty liver disease. Other presentations address important health issues such as e-cigarette usage, geriatric health, cannabinoids, opioid prescribing trends and youth prescription abuse. These are in addition to presentations that discuss ways to improve student learning and general wellness in the population. As you can see, the work being conducted is truly transformational and holds great possibility in evolving our understanding of critically important issues. We believe that this thinking, input and collaboration not only showcases current thinking, but sparks new ideas, new modes of thinking, and imagination. We are proud of the minds and hearts of those in this room today. Thank you to all those responsible for making this important event happen, as well as to all those attending the symposium and supporting the work of colleagues, students and friends. We believe this symposium will continue to grow and serve as a platform for the best thinking and research and a home for sparking imagination, solutions, discovery and learning. Sincerely, Renee Coffman, President Roseman University Research Symposium 2019 Program 3 Dear Colleagues and Guests, Welcome to the 2019 Annual Research Symposium at Roseman University of Health Sciences – the 5th anniversary of this university-wide event that highlights the outstanding research and creative endeavors of Roseman community, students, residents, faculty, researchers, staff and our regional and international guests. It is an opportunity to celebrate the innovation, academic scholarship and creativity and a forum to share the discoveries, insight and performance with a broader audience. The day-long event will take place simultaneously at both campuses in South Jordan, Utah and Henderson, Nevada and will feature 1) keynote speakers, 2) oral and poster presentations, 3) meal, and 4) award presentations. Presentations will be judged by faculty members as well as by qualified guests. We would like to give our heartfelt gratitude to the Keynote speakers, our local organizing team members, volunteers and staff who worked tirelessly to make this event happen. We would also like to thank the sponsors for your generous support which is vital for the success of the symposium. We hope you will find this a dynamic opportunity to learn, network and collaborate with fellow healthcare professionals. Sincerely, Dr. Kamran Awan, BDS, PhD, FPFA, FADI Dr. David Rawlins, PhD Chair, South Jordan Campus Chair, Henderson Campus Associate Professor, College of Dental Medicine Assistant Professor, College of Pharmacy Roseman University of Health Sciences Roseman University of Health Sciences Roseman University Research Symposium 2019 Program 4 Keynote Speaker: South Jordan Rena D’Souza, DDS, MS, PhD President, International Association for Dental Research (IADR), Professor of Dentistry & Assistant Vice President of Academic Affairs & Education, Health Sciences, University of Utah How Science and Technology Advances Impact Oral Health: IADR’s Vision for the Next Century Rena D’Souza is Professor of Dental Sciences, Neurobiology & Anatomy, Pathology and Surgery at the University of Utah. She currently serves as Assistant Vice President for Academic Affairs and Education for the Health Sciences. As a clinician-scientist, D’Souza has been strongly committed to discovery and mentoring throughout her academic career. She is a past president of the American Association for Dental Research (or, AADR) and is the current President of IADR, the largest global dental research organization with about 12,000 members in over 100 countries worldwide.. Dr. D’Souza has authored over 150 publications and book chapters and has maintained an active research program for over 35 years through grant awards from the National Institutes of Health and other agencies. She has also led two major NIH-funded institutional grants that supported the research training of dentists and dentists-scientists at the predoctoral and postdoctoral levels. She received the 2002 Distinguished Scientist Award from the International Association for Dental Research (IADR) and the Presidential Award for Research Excellence from the Texas A&M Health Science Center in 2010. She was also inducted into the German National Academy of Sciences in 2012. Dr. D’souza was recognized as the Columbia University College of Dental Medicine’s Birnberg Research Medal in 2016. Dr. D’Souza is the proud recipient of over 15 dean’s teaching excellence awards and is the 2017 Irwin D. Mandel Distinguished Mentoring Awardee. Roseman University Research Symposium 2019 Program 5 Keynote Speaker: Henderson David R. Powell, MD Senior Vice President, Metabolism Research Pharmaceutical Biology Department Lexicon Pharmaceuticals, Inc. The Woodlands, TX Sotagliflozin as an Adjunct to Insulin for Patients with Type 1 Diabetes Dr. David R. Powell is a Senior Vice President over Metabolism Research at Lexicon Pharmaceuticals. He received his Doctor of Medicine from the University of Medicine and Dentistry of New Jersey following a bachelor’s degree in biology from Rutgers University. Following residencies in Pediatrics, Pediatric Nephrology, and Pediatric Endocrinology at the Medical University of South Carolina, University of California-San Francisco, and Stanford University, Dr. Powell joined Baylor College of Medicine as an Assistant Professor in the Department of Pediatrics, Division of Nephrology. By the time he left Baylor in 2004, he was a Professor of Pediatric Nephrology. He joined Lexicon Pharmaceuticals in The Woodlands, Texas as the Director of Metabolism Research. While at Baylor, Dr. Powell studied ways to treat linear growth failure in children with chronic kidney disease (CKD). His studies demonstrated that growth hormone (GH) increased linear growth in an animal CKD model, a finding that predated clinical data showing that GH improves final adult height of people with CKD. His research group also found that FKHR (now known as FoxO1) was the protein that conferred the negative effect of insulin on hepatic gene transcription. At Lexicon Pharmaceuticals, Dr. Powell has used mouse gene knockouts (KOs) to identify drug targets. His group searched for metabolism drug targets within the nearly 5000 knockouts of druggable genes shared by mice and humans. Through this effort, Dr. Powell identified SGLT1 and SGLT2 as superior targets leading to the development of sotagliflozin (LX4211), an orally delivered dual SGLT1/SGLT2 inhibitor that improved glycemic control in clinical trials. His group has also developed LX2761, an SGLT1 inhibitor restricted to the intestine, which is undergoing clinical trials. They also studied Xermelo, an oral tryptophan hydroxylase (TPH) inhibitor that lowers serotonin production and treats carcinoid syndrome diarrhea, and performed preclinical studies for LX1031, a TPH inhibitor that provided significant relief to subjects with diarrhea- predominant irritable bowel syndrome. He has also developed antibodies that lower lipid levels and developed inhibitors of Notum, a Wnt deacetylase, which are bone anabolic agents. His group has also found a number of other key genes that are involved in obesity and diabetes, including polymorphisms that are linked to diabetes risk, as well as genes that influence bone mass in humans. Roseman University Research Symposium 2019 Program 6 Roseman University of Health Sciences Utah Abstracts Roseman University Research Symposium 2019 Program 7 01: Secretome Analysis of Oral Keratinocytes Chronically Exposed to Shisha Shankargouda Patil;1,2 Niraj Babu;3,4 Tejaswini Subbannayya;3 Sonali V Mohan;3,4 Gajanan Sathe;3 Hitendra S Solanki;3 Pavithra Rajagopalan;3 Krishna Patel;3
Load more

Recommended publications
  • 1 the Following Analysis Addresses Some of the Legal Issues Raised By
    The following analysis addresses some of the legal issues raised by the proposed Utah Medical Marijuana Initiative, which may appear on the ballot in November 2018. The Marijuana Initiative Will Allow Some People to Grow Their Own Marijuana. Holders of medical cannabis cards who live more than 100 miles from a cannabis dispensary would be allowed to grow “up to six cannabis plants for personal medical use ….” (Section 26-60b-201(6)(d).) Nothing in the Initiative allows the State to license or monitor homegrown marijuana operations. The Marijuana Initiative Will Allow People Who Grow Their Own Marijuana to Evade Purchase and Use Limits. The Marijuana Initiative allows users to purchase up to 2 oz. of cannabis (or 10 grams of tetrahydrocannabinol or cannabidiol) from dispensaries every 14 days.1 (Section 26-60b-502(3)-(4).) But nothing in the Initiative prevents a person who is authorized to grow his own marijuana from consuming more than that from his own home- grown plants (which can be very large) or from also buying the maximum amount from a dispensary. The Marijuana Initiative Will Create Significant Challenges for Law Enforcement. Law enforcement will have no way to distinguish between personally-grown legal marijuana and illegal marijuana. Additionally, law enforcement will have no way to distinguish illegally purchased marijuana from legally purchased marijuana. To be sure, a person who has a medical cannabis card who is in possession of cannabis must have “a label that identifies that the cannabis or cannabis product was originally sold from a licensed cannabis dispensary ….” (Section 26-60b-204.) But we see no reason why a cardholder could not keep a label from marijuana bought legally and show it to law enforcement to justify possession of illegally purchased marijuana.
    [Show full text]
  • Planning Commission Hearing Staff Report Hearing Date: October 23, 2019
    Planning Commission Hearing Staff Report Hearing Date: October 23, 2019 ITEM 3* The Provo City Department of Development Services requests an ordinance amendment to Sections 14.06.020; 14.08.020; 14.24.020; 14.26.020; 14.27.020; 14.27A.020; 14.28.020; and 14.29.020, to add a definition for Cannabis Production Establishment, to allow it as a permitted use in the A1.10 Agricultural and the FI Freeway Industrial Zones, and to list that use as not permitted in all other Agricultural and Industrial Zones. City-wide application. Brandon Larsen (801) 852-6408 PLOTA20190365 Applicant: Development Services Relevant History: Medical cannabis has been a frequently addressed subject in recent Utah State legislative sessions, Staff Coordinator: Brandon Larsen including the 2019 First Special Session. Recent amendments to Section 4-41a-406 of the Utah Code, as Property Owner: City-wide well as an inquiry to Development Services regarding the processing of cannabis, have caused staff to consider where cannabis production establishments should be *Council Action Required: Yes permitted within the City. Summary of Key Issues: Amendments to Section 4-41a-406 of the Utah Code provide that cannabis production establishments are permitted in all industrial and all ALTERNATIVE ACTIONS agricultural zones, unless a municipality has 1. Continue to a future date to obtain designated by ordinance at least one industrial zone additional information or to further consider (and at least one agricultural zone) in which the information presented. The next available operation of a cannabis production establishment is a permitted use. meeting date is November 13, 2019, at Staff has received a request for information 6:00 P.M.
    [Show full text]
  • Cannabis: Primer for the Pharmacy Provider
    Annual Meeting September 14, 2019 Medical Cannabis: Primer for the Pharmacy Provider Brad Winter, PharmD, BCACP Sarah Yost, PharmD, BCPS Ambulatory Clinical Pharmacists Disclosure Instructions: Authors have no conflicts of interest to disclose. Presentation will include discussion of off-label medication use. INTERMOUNTAIN HEALTHCARE AND AUTHORS HAVE NOT RESEARCHED OR INDEPENDENTLY VALIDATED ANY ASSERTIONS OR CLAIMS AS TO THE USE OF CANNABIS AS DESCRIBED IN THIS PRESENTATION. AS SUCH, INTERMOUNTAIN HEALTHCARE AND AUTHORS OFFERS NO ASSURANCE AS TO THE CANNABIS INFORMATION DESCRIBED HEREIN, ANY SUCH RELIANCE AND LIABILITY IS SOLELY ON THE INDIVIDUAL REVIEWING AND RELYING UPON ANY USE OF CANNABIS. Learning Objectives At the conclusion of this activity, pharmacists should be able to successfully: 1. Differentiate between tetrahydrocannabinol (THC) and cannabidiol (CBD) 2. Review available cannabinoid formulations that are allowed in the state of Utah 3. Review available literature for cannabis use in various qualifying conditions 4. Describe key details of the Utah Medical Cannabis Act Learning Objectives At the conclusion of this activity, pharmacy technicians should be able to successfully: 1. Differentiate between tetrahydrocannabinol (THC) and cannabidiol (CBD) 2. Review available cannabinoid formulations that are allowed in the state of Utah 3. Describe key details of the Utah Medical Cannabis Act Definitions Cannabis ‐ generic term for drugs produced from plants of the genus Cannabis Cannabinoid ‐ group of compounds produced by cannabis
    [Show full text]
  • December 1–2, 2018, LNC Meeting Minutes
    MEETING MINUTES LIBERTARIAN NATIONAL COMMITTEE DECEMBER 1-2, 2018 ALEXANDRIA, VA PREPARED BY CARYN ANN HARLOS, LNC SECRETARY CURRENT STATUS: FINAL LAST REVISION DATE: 3/8/19 TABLE OF CONTENTS OPENING CEREMONY 5 CALL TO ORDER 5 OPPORTUNITY FOR PUBLIC COMMENT 5 HOUSEKEEPING 5 ATTENDANCE, CREDENTIALS, AND PAPERWORK CHECK 5 ADOPTION OF THE AGENDA 6 REPORT OF POTENTIAL CONFLICTS OF INTEREST 9 OFFICER REPORTS 9 CHAIR’S REPORT 9 VICE-CHAIR’S REPORT 10 TREASURER’S REPORT 10 SECRETARY’S REPORT 11 APPROVAL OF THE SEPTEMBER 29-30, 2018 LNC MINUTES 11 STAFF REPORTS 12 SPECIAL COUNSEL’S REPORT 13 STAFF REPORTS CONT’D 14 VISTACOM PRESENTATION 14 REPORTS OF STANDING COMMITTEES 14 AUDIT COMMITTEE 14 AFFILIATE SUPPORT COMMITTEE 14 CONVENTION OVERSIGHT COMMITTEE 14 EMPLOYMENT POLICY AND COMPENSATION COMMITTEE 15 HISTORICAL PRESERVATION COMMITTEE 15 INFORMATION TECHNOLOGY COMMITTEE 15 BALLOT ACCESS COMMITTEE 16 NEW BUSINESS WITH PREVIOUS NOTICE 16 ADOPTION OF 2019 BUDGET 16 EXECUTIVE SESSION 17 EVENING ADJOURNMENT 17 SUNDAY MORNING SESSION 17 CALL TO ORDER 17 OPPORTUNITY FOR PUBLIC COMMENT 17 LNC – ALEXANDRIA, VA – DECEMBER 1-2, 2018 – FINAL Page 2 APPROVAL OF PRIOR MEETING MINUTES CONT’D 17 REPORTS OF SPECIAL COMMITTEES 18 BLOCKCHAIN COMMITTEE 18 YOUTH ENGAGEMENT COMMITTEE 18 CONVENTION VOTING PROCESS COMMITTEE 18 MEMBERSHIP SUPPORT COMMITTEE 18 REGIONAL REPORTS 18 REGION 1 REPORT 18 REGION 2 REPORT 19 REGION 3 REPORT 19 REGION 4 REPORT 19 REGION 5 REPORT 19 REGION 6 REPORT 21 REGION 7 REPORT 21 REGION 8 REPORT 21 NEW BUSINESS WITH PREVIOUS NOTICE
    [Show full text]
  • Utah Medical Cannabis Program February 2021 Update
    UTAH MEDICAL CANNABIS PROGRAM FEBRUARY 2021 UPDATE Table of Contents Important Program Deadlines and Dates..............................2 Pharmacy Updates..........................................................................3 Home Delivery Available...........................................................3 New Pharmacy Open.............................................................3 Public Notices...................................................................................3 Cannabinoid Product Board Meeting..................................3 2021 General Session.............................................................3 News and Press Releases.............................................................4 Utah Program Product Trends Report................................4 EVS and ICS Announcements.....................................................5 QMPs: Ongoing EVS Errors...................................................5 Utah Medical Cannabis Program Monthly Report.............6 288 North 1460 West, Salt Lake City, UT 84116 T: (801) 538-6504 | [email protected] | medicalcannabis.utah.gov FEBRUARY 2021 UPDATE | 2 IMPORTANT PROGRAM DEADLINES AND DATES January 1, 2021 As of this date, patients may no longer use recommendation letters to purchase product from medical cannabis pharmacies. Patients must now hold a valid medical cannabis card in order to legally purchase and possess medical cannabis. Pharmacies cannot accept recommendation letters in place of medical cannabis cards. Medical cannabis cards are valid
    [Show full text]
  • Medical Marijuana Resources
    MEDICAL CANNABIS AND PARENTAL/YOUTH USE TODAY’S TOPICS THE GOOD, THE BAD, AND THE Q&A TODAY’S TOPICS THE GOOD, THE BAD, AND THE Q&A WHO ARE WE? TODAY’S TOPICS THE GOOD, THE BAD, AND THE Q&A WHO ARE WE? BRIEF OVERVIEW OF UTAH MEDICAL CANNABIS ACT TODAY’S TOPICS THE GOOD, THE BAD, AND THE Q&A WHO ARE WE? BRIEF OVERVIEW OF UTAH MEDICAL CANNABIS ACT JUVENILE-SPECIFIC INFO TODAY’S TOPICS THE GOOD, THE BAD, AND THE Q&A WHO ARE WE? BRIEF OVERVIEW OF UTAH MEDICAL CANNABIS ACT JUVENILE-SPECIFIC INFO QUESTIONS? Key Point: We didn’t legalize medical cannabis in Utah only for childless adults. • Marijuana: dried flowers and leaves of the cannabis plant • Marijuana: dried flowers and leaves of the cannabis plant • Contains over 420 chemical compounds • Marijuana: dried flowers and leaves of the cannabis plant • Contains over 420 chemical compounds • including over 60 belonging to chemical group of cannabinoids with psychoactive (mood changing) properties • Marijuana: dried flowers and leaves of the cannabis plant • Contains over 420 chemical compounds • including over 60 belonging to chemical group of cannabinoids with psychoactive (mood changing) properties • Cannabinoids: primarily concentrated in flowers (less concentrated in leaves and stems) • Marijuana: dried flowers and leaves of the • Amount and mixtures of cannabinoids vary with cannabis plant species of the plant, growing practices, timing of the harvest • Contains over 420 chemical compounds • including over 60 belonging to chemical group of cannabinoids with psychoactive (mood changing)
    [Show full text]
  • Center for Medical Cannabis Annual Report
    Report to the Utah State Legislature Health and Human Services Interim Committee Center for Medical Cannabis Utah Department of Health 2020 Annual Report November 17, 2020 1 TABLE OF CONTENTS 1. Introduction .................................................................................................................................... 3 2. Center Background and Duties ....................................................................................................... 3 3. Center Achievements ..................................................................................................................... 3 4. Market Analysis .............................................................................................................................. 6 5. Patient Registrations ...................................................................................................................... 6 Table 1. Cardholders, Caregivers, and Recommendation Letter Customers ................................... 6 Figure 1. Active Patient Cardholders by Month .............................................................................. 7 Table 2. Patient Demographics by Age and Sex .............................................................................. 7 Table 3. Patient Cardholders by County of Residence .................................................................... 8 Table 4. Patient Cardholders by Medical Condition ....................................................................... 9 Table 5. Petitions to the Compassionate
    [Show full text]
  • Official Conference Guide New Orleans Morial Convention Center
    OFFICIAL CONFERENCE GUIDE NEW ORLEANS MORIAL CONVENTION CENTER MJBIZCON.COM/NEXT LETTER FROM THE PRESIDENT & CEO Welcome to the newest addition in the family of MJBizCon events: MJBizConNEXT! MJBizDaily is always focused on the evolving education and networking needs of the cannabis industry. As we look to 2018 and beyond, providing a platform for the industry to thinking and acting with more long-term vision has become paramount. As young as the industry still remains, we’ve achieved a point of maturity where best practices and repeatable models are established and now being refined. As a result, MJBizConNEXT has been designed from the ground up to showcase to the cannabis industry – and the broader audience watching us – what the possibilities beyond the current horizon are for this marketplace. As the cannabis industry continues to build new models for business solutions and adapt best practices from other industries to apply to our own unique needs, it is important that the professionals building a path forward solve for today’s challenges and those of tomorrow. There is plenty on offer here for professionals at all stages of their cannabis careers. What’s NEXT for you: winning a plant-touching license? Jumping the gap to getting your doors open? Scaling your business by swapping the latest techniques with other experts? Or perhaps you’re prepping for an M&A event. Whatever your goal, there is a session, connection or business solution ready to help you get to the next level at MJBizConNEXT. At this event, we aren’t just preparing for what’s next for the cannabis industry.
    [Show full text]
  • Cannabis Cures: American Medicine, Mexican Marijuana, and the Origins of the War on Weed, 1840-1937
    Cannabis Cures: American Medicine, Mexican Marijuana, and the Origins of the War on Weed, 1840-1937 Author: Adam R. Rathge Persistent link: http://hdl.handle.net/2345/bc-ir:107531 This work is posted on eScholarship@BC, Boston College University Libraries. Boston College Electronic Thesis or Dissertation, 2017 Copyright is held by the author. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http:// creativecommons.org/licenses/by-nc-nd/4.0). Cannabis Cures: American Medicine, Mexican Marijuana, and the Origins of the War on Weed, 1840-1937 Adam R. Rathge A dissertation submitted to the Faculty of the Department of History in partial fulfillment of the requirements for the degree of Doctor of Philosophy Boston College Morrissey College of Arts and Sciences Graduate School May 2017 © Copyright 2017 Adam R. Rathge CANNABIS CURES: AMERICAN MEDICINE, MEXICAN MARIJUANA, AND THE ORIGINS OF THE WAR ON WEED, 1840-1937 Adam R. Rathge Advisor: Martin A. Summers, Ph.D. This dissertation charts the medicalization and criminalization of the drug now widely known as marijuana. Almost no one in the United States used that word, however, until it was introduced from Mexico in the early twentieth century. Prior to that, Americans often called it hemp or hashish, and generally knew it as Cannabis - the scientific name given to a genus of plants by Carl Linnaeus. That transition in terminology from cannabis to marijuana serves as the crux of this project: It begins in 1840 with the formal introduction of cannabis into American medicine and ends in 1937 with the federal prohibition of marijuana.
    [Show full text]
  • Utah Medical Cannabis
    10-04-18 DRAFT 2019FL-4444/020 1 UTAH MEDICAL CANNABIS ACT 2 2019 GENERAL SESSION 3 STATE OF UTAH 4 5 LONG TITLE 6 General Description: 7 This bill provides for the cultivation, processing, medical recommendation, and patient 8 use of medical cannabis. 9 Highlighted Provisions: 10 This bill: 11 < defines terms; 12 < provides for licensing and regulation of a cannabis cultivation facility, a cannabis 13 processing facility, an independent cannabis testing laboratory, and a medical 14 cannabis pharmacy; 15 < provides for security and tracking of cannabis and a cannabis product from 16 cultivation to consumption to ensure safety and chemical content; 17 < requires certain labeling and childproof packaging of cannabis and a cannabis 18 product; 19 < requires the Department of Agriculture and Food, the Department of Health, the 20 Department of Public Safety, and the Department of Technology Services to create 21 an electronic verification system to facilitate recommendation, dispensing, and 22 record-keeping for medical cannabis transactions; 23 < allows an individual with a qualifying condition to obtain a medical cannabis card 24 on the recommendation of a certain medical professional to gain access to medical 25 cannabis; 26 < allows a patient to designate a caregiver to assist with accessing medical cannabis; 27 < provides that a parent or legal guardian is the designated caregiver for a minor; 28 < provides housing and employment discrimination protection for an individual who 29 lawfully uses medical cannabis; 30 < limits the form and
    [Show full text]
  • January 2021 Update
    UTAH MEDICAL CANNABIS PROGRAM JANUARY 2021 UPDATE Table of Contents Important Program Deadlines and Dates..............................2 Pharmacy Updates..........................................................................3 Medical Cannabis Courier Application................................3 Public Notices...................................................................................3 Cannabinoid Product Board Meeting..................................3 2021 General Session.............................................................3 News and Press Releases.............................................................3 Spanish Application Guides Available................................3 EVS and ICS Announcements.....................................................4 QMPs: Ongoing EVS Errors...................................................4 Utah Medical Cannabis Program Monthly Report.............5 288 North 1460 West, Salt Lake City, UT 84116 T: (801) 538-6504 | [email protected] | medicalcannabis.utah.gov JANUARY 2021 UPDATE | 2 IMPORTANT PROGRAM DEADLINES AND DATES January 1, 2021 As of this date, patients may no longer use recommendation letters to purchase product from medical cannabis pharmacies. Patients must now hold a valid medical cannabis card in order to legally purchase and possess medical cannabis. Any cannabis product in an individual’s possession must have been purchased from a licensed Utah medical cannabis pharmacy. Cannabis product purchased outside Utah may no longer be legally possessed in Utah. For
    [Show full text]
  • Utah Medical Cannabis Act Overview Updated As of December 12, 2018
    Utah Medical Cannabis Act Overview Updated as of December 12, 2018 Plant 8” Tall Cultivators (10-15 max) Independent Cannabis Testing Laboratory Processors Electronic Verification State Central Fill provides for security and System Medical Cannabis tracking of cannabis and a Pharmacy/Pharmacies related product from Pharmacies (7-10) cultivation to patient use. Local Health Department Inventory Control System Control Inventory (13+) Qualified Medical Provider (MD,DO, APRN, or PA) Medical Cannabis Cardholder red arrows indicate regulated Patient Use transportation and distribution access to state electronic verification system MEMORANDUM To: Physician Assistant Licensing Board From: Richard J. Oborn, Director, Center for Medical Cannabis, Utah Department of Health Date: Thursday, March 7, 2019 Subject: Request for Input Regarding Utah Medical Cannabis Act Continuing Education Requirement Utah Code 26-61a-106 (3) (c) directs the Utah Department of Health (DOH) to consult with the Division of Occupational and Professional Licensing (DOPL) and the Physician Assistant Licensing Board regarding the development of continuing education requirements for qualified medical providers registered under the Utah Medical Cannabis Act. Once input is received, the DOH plans to draft and file administrative rules outlining the continuing education requirement. The DOH has coordinated with the Utah Medical Association to draft some course criteria that it would like to submit for the Board’s review. Qualified Medical Provider - Continuing Education Requirement Utah Code 26-61a-106 (3) requires that an individual, as a requirement to be registered as a qualified medical provider, verify completion of four hours of continuing education. Furthermore, once registered as a qualified medical provider, an individual must complete an additional four hours of continuing education every two years as a requirement for renewal.
    [Show full text]